NeuroAIDS, drug abuse, and inflammation: Building collaborative research activities

Journal of Neuroimmune Pharmacology

Volumn 1, Issue 4, 2006, Pages 351-399

  Berman, Joan W ^a   Carson, Monica J ^b   Chang, Linda ^c   Cox, Brian M ^d   Fox, Howard S ^e   Gonzalez, R Gilberto ^f   Hanson, Glen R ^g   Hauser, Kurt F ^h   Ho, Wen Zhe ⁱ   Hong, Jau Shyong ^j   Major, Eugene O ^k   Maragos, William F ^h   Masliah, Eliezer ^l   McArthur, Justin C ^m   Miller, Diane B ⁿ   Nath, Avindra ^m   O'Callaghan, James P ⁿ   Persidsky, Yuri ^o   Power, Christopher ^p   Rogers, Thomas J ^q   Royal III, Walter ^r   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^j NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^k NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^l UCSD MEDICAL CENTER   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^o UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^p UNIVERSITY OF ALBERTA   (Canada)

^q TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Brain; Drug abuse; HIV; Inflammation; NeuroAIDS; SIV

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; ANIMAL; BRAIN; COOPERATION; HUMAN; IMMUNOLOGY; INFLAMMATION; MEDICAL RESEARCH; METHODOLOGY; PATHOLOGY; REVIEW;

AIDS DEMENTIA COMPLEX; ANIMALS; BIOMEDICAL RESEARCH; BRAIN; COOPERATIVE BEHAVIOR; HUMANS; INFLAMMATION; SUBSTANCE-RELATED DISORDERS;

EID: 33751255432     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-006-9048-9     Document Type: Review

References (127)

1. Aguet M, Mogensen KE (1983) Interferon receptors. Interferon 5:1-22
2. Amemiya K, Traub R, Durham L, Major EO (1992) Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC Virus. J Biol Chem 267:14204-14211
3. Baucum AJ, Rau K, Riddle E, Hanson GR, Fleckenstein AE (2004) Methamphetamine increases dopamine transporter oligomer formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24:3436-3443
4. Benkovic SA, O'Callaghan JP, Miller DB (2004) Sensitive indicators of injury reveal hippocampal damage in C57BL/6J mice treated with kainic acid in the absence of tonic-clonic seizures. Brain Res 1024:59-76
5. Block M, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77-98
6. Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, Wilson B, Yang J, Hong JS (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 20:251-258
7. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289-298
8. Brown JM, Gouty S, Iyer V, Rosenberger J, Cox BM (2006) Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem 98:495-505
9. Buckner CM, Luers AJ, Calderon TM, Eugenin EA, Berman JW (2006) Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on NeuroAIDS. J Neuroimmune Pharm 1:160-181
10. Capitanio JP, Mendoza SP, Lerche NW, Mason WA (1998) Social stress results in altered glucocorticoid regulation and shorter survival in simian acquired immune deficiency syndrome. Proc Natl Acad Sci 95:4714-4719
11. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix C (2006) CNS immune privilege: hiding in plain sight. Immunol Rev 213:48-65
12. Chang L, Cloak C, Yakupov R, Ernst T (2006) Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J NeuroImmune Pharmacol 1:65-76
13. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E (1999a) Cerebral metabolite abnormalities correlate with clinical severity of HIV-cognitive motor complex. Neurology 52:100-108
14. Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller EN (1999b) Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53:782-789
15. Chang L, Ernst T, Speck O, Grob C (2005) Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychol 162:361-369
16. Chang L, Ernst T, St Hillaire C, Conant K (2004) Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 9:431-440
17. Chang L, Ernst T, Witt M, Ames N, Jocivich J, Speck O, Gaiefsky M, Walot I, Miller E (2002) Relationships among cerebral metabolites, cognitive function and viral loads in antiretroviral-naïve HIV patients. NeuroImage 17:1638-1648
18. Ciborowski P, Gendelman HE (2006) Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis. Curr HIV Res 4(3):279-291
19. Cloak CC, Chang L, Ernst T (2004) Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J Neuroimmunol 157:147-152
20. Conant K, Garzino-Demo A, Nath A, McArthur J, Halliday W, Power C, Gallo R, Major E (1998) Induction of monocyte chemoattractant protein-1 in HIV-1 tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 95:3117-3121
21. D'Aversa T, Yu KO, Berman JW (2004) Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein tat. J Neurovirology 10(2):86-97
22. D'Aversa TG, Eugenin EA, Berman JW (2005) NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins tat and gp120 as well as CD40 to microglial activation. J Neurosci Res 81(3):436-446
23. Dafny N (1998) Is interferon-alpha a neuromodulator? Brain Res Brain Res Rev 26:1-15
24. Dafny N, Yang PB (2005) Interferon and the central nervous system. Eur J Pharmacol 523:1-15
25. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, Staeheli P, Michiels T (2006) Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci USA 103:7835-7840
26. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE (2006) Development of a macrophage-based nanoparticle system for anti-retroviral drug delivery. Blood 108(8):2827-2835
27. Eisenstein TK, Bussiere JL, Rogers TJ, Adler MW (1993) Immunosuppressive effects of morphine on immune responses in mice. Adv Exp Med Biol 335:41-52
28. Eledrisi MS, Verghese AC (2001) Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci 321:137-144
29. 2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50:91-106
30. El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF (2006a) CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 178 (1-2):9-16
31. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF (2006b) HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53:132-146
32. Ernst T, Chang L, Arnold S (2003) Increased glial markers predict increased working memory network activation in HIV patients. NeuroImage 19:1686-1693
33. Eugenin EA, Dyer G, Calderon TM, Berman JW (2005) HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1) dependent mechanism: a possible role in NeuroAIDS. Glia 49:501-510
34. Eugenin EA, Gamss R, Buckner C, Buono D, Klein RS, Schoenbaum EE, Calderon TM, Berman JW (2006a) Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J Leukoc Biol 79:444-452
35. Eugenin EA, Osieki K, Lopez L, Goldstein H, Calderon TM, Berman JW (2006b) CCL2/Monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanisms of HIV-CNS invasion and NeuroAIDS. J Neurosci 26(4):1098-1106
36. Everall I, Barnes H, Spargo E, Lantos P (1995) Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats. J Neurovirology 1:126-129
37. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9:209-217
38. Fiala M, Eshleman AJ, Cashman J, Lin J, Lossinsky AS, Suarez V, Yang W, Zhang J, Popik W, Singer E, et al. (2005) Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirology 11:281-291
39. Fleckenstein AE, Hanson GR (2003) Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 479:283-289
40. Fox HS, Weed MR, Huitron-Resendiz S, Baig J, Horn TFW, Dailey PJ, Bischofberger N, Henriksen SJ (2000) Normalization of CNS evoked potential but not movement abnormalities by antiviral treatment in SIV-infected monkeys. J Clin Invest 106:37-45
41. Freda PU, Bilezikian JP (1999) The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read 9:43-50
42. Fujimura RK, Goodkin K, Petito CK, Douyon R, Feaster DJ, Concha M, Shapshak P (1997) HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia. J Acquir Immune Defic Syndr Human Retrovirol 16:146-152
43. Gallo V, Chittajallu R (2001) Neuroscience: unwrapping glial cells from the synapse: what lies inside? Science 292:872-873
44. Gao H, Hong JS, Zhang W, Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782-790
45. Gavrilin MA, Mathes LE, Podell M (2002) Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirology 8:240-249
46. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK (2002) HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 99:13795-13800
47. Hanson GR, Rau KS, Fleckenstein AE (2004a) The Methamphetamine Experience: a NIDA Partnership. Neuropharmacology 47:92-100
48. Hanson GR, Sandoval V, Riddle E, Fleckenstein AE (2004b) Psychostimulant and vesicle trafficking: a novel mechanism and therapeutic implications. Ann NY Acad Sci 1025:146-150
49. Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ, Knapp PE (2005) Molecular targets of opiate drug abuse in NeuroAIDS. Neurotox Res 8:63-80
50. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE (1998) Beta-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 44:831-835
51. Kim WG, Wilson BC, Jeohn GH, Hong JS (2000) Differential susceptivity of neurons in different brain regions in lipopolysaccharide (LPS)-induced neurotoxicity. J Neurosci 20:6309-6316
52. King JE, Eugenin EA, Buckner CM, Berman JW (2006) HIV tat and neurotoxicity. Microbes Infect 8(5):1347-1357
53. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319
54. Kopnisky KL, Stoff DM, Rausch DM (2004) Workshop report: the effects of psychological variables on the progression of HIV-1 disease. Brain Behav Immun 18:246-261
55. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P (2002) Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 109:399-410
56. Kumar M, Kumar AM, Waldrop D, Antoni MH, Eisdorfer C (2003) HIV-1 infection and its impact on the HPA axis, cytokines, and cognition. Stress 6:167-172
57. Langer J, Garotta G, Pestka S (1996) Interferon receptors. Biotherapy 8:163-174
58. Laudenbach V, Calo G, Guerrini R, Lamboley G, Bernoist J-F, Evrard P, Gressens P (2001) Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. J Clin Invest 1007:457-466
59. Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO (2004) Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 78:7319-7328
60. Lawrence DM, Seth P, Durham L, Diaz F, Boursiquot R, Ransohoff RM, Major EO (2006) Astrocyte differentiation selectively upregulates CCL2/monocyte chemoattractant protein-1 in cultured human brain-derived progenitor cells. Glia 53:81-91
61. Lentz MR, Kim JP, Westmoreland SV, Greco JB, Fuller RA, Ratai EM, He J, Sehgal PK, Halpern F, Lackner AA, Masliah E, Gonzalez RG (2005) Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 235:461-468
62. Liu Y, Qin L, Wilson B, Hong JS, Liu B (2002) Inhibition of naloxone stereoisomers of β-amyloid peptide-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302:1212-1219
63. Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SH, Henriksen SJ, Fox HS (2005) Modeling human methamphetamine exposure in non-human primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30:350-359
64. Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP, Nair MP (2002) Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol 169:3589-3599
65. Maragos WF, Young KL, Altman CA, Turchan JT, Pauly, JR, Guseva M, Nath A, Cass WA (2002) HIV-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83:955-963
66. Marcondes MCG, Burudi EME, Huitron-Resendiz S, Sanchez-Alvarez M, Watry D, Zandonatti M, Henriksen SJ, Fox HS (2001) Highly activated CD8+ T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection. J Immunol 167:5429-5438
67. Marti M, Guerrini R, Beani L, Bianchi C, Morari M (2002) Nocicpetin/orphanin FQ receptors modulate glutamate extracellular levels in the substania nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112:153-160
68. Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, Morari M (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 25:9591-9601
69. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA (1992) Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51:585-593
70. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 42:963-972
71. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543-555
72. Messam CA, Hou J, Gronostajski RM, Major EO (2003) Lineage pathway of human brain progenitor cells identified by JC virus susceptibility. Ann Neurol 53:636-646
73. Miller DB, O'Callaghan JP (2002) Neuroendocrine aspects of the response to stress. Metabolism 51(Suppl 1):5-10
74. Miller DB, O'Callaghan JP (2005) Aging, stress and the hippocampus. Ageing Res Rev 4:123-140
75. Nair MP, Mahajan S, Hewitt R, Whitney ZR, Schwartz SA (2004) Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. J Neuroimmunol 147:21-25
76. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC (1997) Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 4:127-132
77. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W, Turchan JT (2002) Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31(Suppl 2):S62-S69
78. Nath A, Jones M, Maragos W, Booze RM, Mactutus C, Bell J, Mattson M (2000) Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14:222-227
79. Navia BA, Cho ES, Petito CK, Price RW (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19:525-535
80. O'Callaghan JP, Sriram K (2005) GFAP and other glial proteins as biomarkers of neurotoxicity. Exp Opin Drug Saf 4:433-442
81. Pandya R, Krentz HB, Gill MJ, Power C (2005) HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 32:201-204
82. Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA, Shimokawa H, Kaibuchi K, Ikezu T (2006b) Rhomediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107:4770-4780
83. Persidsky Y, Ramirez S, Haorah J, Kanmogne G (2006a) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223-236
84. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Ann Rev Biochem 56:727-777
85. Peterson PK, Gekker G, Hu S, Lokensgard J, Portoghese PS, Chao CC (1999) Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology 38:273-278
86. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF (1987) Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 80:824-831
87. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr (1990) Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 4:869-873
88. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y (2005) Inhibition of Indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in animal model of HIV-1 encephalitis. Blood 106:2383-2390
89. Qin L, Block M, Liu Y, Bienstock R, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS (2005) Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 19:550-557
90. Rau K, Birdsall E, Volz T, Riordan J, Baucum A, Adair B, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE (2006) Methamphetamine administration reduces hippocampal VMAT-2 uptake. J Pharmacol Exp Ther 318:676-682
91. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991) Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82:39-44
92. Riddle E, Fleckenstein AE, Hanson GR (2006) Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. J Am Assoc Pharm Sci 8:E413-E418
93. Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. J Am Assoc Pharm Sci 7:E847-E851
94. Riddle EL, Topham M, Haycock J, Hanson G, Fleckenstein A (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74
95. Roberts ES, Burudi EME, Flynn C, Madden LJ, Roinick KL, Watry DD, Zandonatti MA, Taffe MA, Fox HS (2004a) Acute SIV infection of the brain leads to upregulation of IL6 and interferon-regulated genes: expression patterns throughout disease progression and impact on NeuroAIDS. J Neuroimmunol 157:81-92
96. Roberts ES, Huitron-Resendiz S, Taffe MA, Marcondes MC, Flynn CT, Lanigan CM, Hammond JA, Head SR, Henriksen SJ, Fox HS (2006) Host response and dysfunction in the CNS during chronic SIV infection. J Neurosci 26:4577-4585
97. Roberts ES, Masliah E, Fox HS (2004b) CD163 identifies a unique population of ramified microglia in HIV encephalitis. J Neuropathol Exp Neurol 63:1255-1264
98. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, Taffe MA, Fox HS (2003) Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. Am J Pathol 162:2041-2057
99. Rogers TJ, Peterson PK (2003) Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24:116-121
100. Sloan EK, Tarara RP, Capitanio JP, Cole SW (2006) Enhanced replication of simian immunodeficiency virus adjacent to catecholaminergic varicosities in primate lymph nodes. J Virol 80:4326-4335
101. Song H, Stevens CF, Gage FH (2002) Astroglia induce neurogenesis from adult neural stem cells. Nature 417:39-44
102. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2006a) Microglial activation and MPTP-induced neurotoxicity: region-specific role for TNF-α. FASEB J 20:670-682
103. Sriram K, Miller DB, O'Callaghan JP (2006b) Minocyline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of TNF-α. J Neurochem 96:706-719
104. Steele AD, Henderson EE, Rogers TJ (2003) Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309:99-107
105. Steele AD, Szabo I, Bednar F, Rogers TJ (2002) Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev 13:209-222
106. Stiene-Martin A, Knapp PE, Martin KM, Gurwell JA, Ryan S, Thornton SR, Smith FL, Hauser KF (2001) Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo. Glia 36:78-88
107. Stiene-Martin A, Zhou R, Hauser KF (1998) Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa opioid receptor expression among cultured mouse astrocytes. Glia 22:249-259
108. Stoll-Keller F, Schmitt C, Thumann C, Schmitt MP, Caussin C, Kirn A (1997) Effects of morphine on purified human blood monocytes. Modifications of properties involved in antiviral defences. Int J Immunopharmacol 19:95-100
109. Streit WJ, Walter SA, Pennell NA (1999) Reactive microgliosis. Prog Neurobiol 57:563-581
110. Svendsen CN (2002) The amazing astrocyte. Nature 417:29-32
111. Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY, Bednar F, Henderson EE, Howard OM, Oppenheim JJ, Rogers TJ (2003) Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. J Leukoc Biol 74:1074-1082
112. Theodore S, Cass WA, Maragos WF (2006a) Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol 199:490-498
113. Theodore S, Cass WA, Maragos WF (2006b) Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137:925-935
114. Theodore S, Nath A, Young K, Cass WA, Maragos WF (2006c) Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein tat and methamphetamine interaction. Neurobiol Dis, July 5 [Epub ahead of print]
115. Theodore S, Stolberg S, Cass WA, Maragos WF (2006d) Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann NY Acad Sci 1074:178-190
116. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, Peng X, Chen K, Chauhan A, Haughey N, Cutler R, Mattson MP, Pardo C, Conant K, Sacktor N, McArthur J, Hauser KF, Gairola C, Nath A (2006) Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 23:109-119
117. van Marle G, Power C (2005) Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant? J Neurovirology 11:107-128
118. Volkow N, Chang L, Wang G, Fowler J, Ding Y, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, et al (2001a) Low level of brain dopamine d(2) receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychol 158:2015-2021
119. Volkow N, Chang L, Wang G, Fowler J, Leonido-Yee M, Franceschi D, Sedler M, Gatley S, Hitzemann R, Ding Y, et al (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychol 158:377-382
120. Volz TJ, Hanson GR, Fleckenstein AE (2006) Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J Neurosci Methods 155:109-115
121. Wang G, Chang L, Volkow N, Telang F, Logan J, Ernst T, Fowler J (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127:2452-2458
122. Webster JI, Sternberg EM (2004) Role of the hypothalamic-pituitary- adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol 181:207-221
123. Wetzel MA, Steele AD, Eisenstein TK, Adler MW, Henderson EE, Rogers TJ (2000) Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol 165:6519-6524
124. Williams K, Westmoreland S, Greco J, Ratai E, Lentz M, Kim WK, Fuller RA, Kim JP, Autissier P, Sehgal PK, Schinazi RF, Bischofberger N, Piatak M, Lifson JD, Masliah E, Gonzalez RG (2005) Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV Neuro-AIDS. J Clin Invest 115:2534-2545
125. Witta J, Buzas B, Cox BM (2003) Traumatic brain injury induces nociceptin/orphanin FQ expression in neurons of the rat cerebral cortex. J Neurotrauma 20(6):523-532
126. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771
127. Zhang W, Qin L, Wang T, Wei S, Gao H, Liu J, Wilson B, Liu B, Zhang W, Kim H, Hong JS (2005) 3-Hydroxy-morphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 19:395-397